Press release
Atopic Dermatitis Pipeline and Clinical Trials Assessment (2023) | Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma,
Atopic Dermatitis Pipeline
The Atopic Dermatitis pipeline analysis report for Atopic Dermatitis emerging drugs offers a comprehensive and holistic perspective of the therapeutic landscape. It encompasses the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Atopic Dermatitis pipeline covers multiple facets including business opportunities, challenges, potential partnerships, formidable competitors, and growth strategies. Each drug is described in detail, including its mechanism of action, Atopic Dermatitis clinical trial studies conducted for Atopic Dermatitis, any obtained Atopic Dermatitis NDA approvals, and product development activities such as technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other pertinent information.
To explore more information on the latest breakthroughs in the Atopic Dermatitis Pipeline treatment landscape of the report, click here @ Atopic Dermatitis Pipeline Outlook- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Atopic Dermatitis Pipeline Report
• DelveInsight's Atopic Dermatitis Pipeline analysis depicts a robust space with 100+ active players working to develop 110+ pipeline treatment therapies.
• The leading Atopic Dermatitis Companies are working in the market include Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and many others.
• Promising Atopic Dermatitis Pipeline Therapies in the various stages of development includes Baricitinib, Dupilumab, Lebrikizumab, and others.
• In November 2022, Alphyn Biologics announced that it had completed the first cohort of its Phase IIa clinical trial of AB-101a, a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old. The first cohort enrolled AD patients without bacterial infection, which is sometimes associated with the disease. Top-line results are expected in approximately eight weeks.
• In September 2022, selectION announced that it has begun dosing patients in a Phase Ib trial to evaluate safety and efficacy, including duration of clinical benefit, of si-544 in patients with mild to severe atopic dermatitis.
• In July 2022, Connect Biopharma Holdings announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration (CDE), that it can conduct primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 to treat adult patients with moderate-to-severe atopic dermatitis (AD) based on the 255 patients. As a result, Connect Biopharma plans to report this trial's top-line results by year-end, earlier than originally planned.
• In May 2022, Brickell Biotech announced that the first subjects were dosed in the single ascending dose of Phase I clinical trial evaluating BBI-02 in healthy adult subjects and patients with atopic dermatitis. BBI-02 is a potential first-in-class, highly selective, orally bioavailable small molecule DYRK1A inhibitor that aims to restore immune balance through modulating adaptive and innate immune responses in patients with autoimmune and inflammatory diseases.
Atopic Dermatitis Overview
Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red,swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over time. While the conditionmay occur at any age, it typically starts in childhood with changing severity over the years. In children under one year of agemuch of the body may be affected. As children get older, the back of the knees and front of the elbows are the most commonareas affected.
For further information, refer to the detailed Atopic Dermatitis Unmet Needs, Atopic Dermatitis Market Drivers, and Atopic Dermatitis Market Barriers, click here for Atopic Dermatitis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Atopic Dermatitis Emerging Drugs Profile
• Tapinarof: Dermavant Sciences
• Etrasimod: Pfizer
• B244: AOBiome
• Lirentelimab: Allakos Inc.
• QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis Pipeline Therapeutics Assessment
There are approx. 100+ Atopic Dermatitis companies which are developing the Atopic Dermatitis therapies. The Atopic Dermatitis companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. phase III include, Dermavant Sciences.
Request a sample and discover the recent advances in Atopic Dermatitis Ongoing Clinical Trial Analysis and Medications, click here @ Atopic Dermatitis Treatment Landscape- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Atopic Dermatitis Pipeline Segmentation
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Atopic Dermatitis Therapeutics Market include-
Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and many others.
Dive deep into rich insights for drugs for Atopic Dermatitis Pipeline, click here @ Atopic Dermatitis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Atopic Dermatitis Pipeline Report
• Coverage- Global
• Atopic Dermatitis Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and many others.
• Atopic Dermatitis Pipeline Therapies- Baricitinib, Dupilumab, Lebrikizumab, and others
• Atopic Dermatitis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Atopic Dermatitis Mergers and acquisitions, Fe Atopic Dermatitis Licensing Activities @ Atopic Dermatitis Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Atopic Dermatitis Executive Summary
3. Atopic Dermatitis: Overview
4. Atopic Dermatitis Pipeline Therapeutics
5. Atopic Dermatitis Therapeutic Assessment
6. Atopic Dermatitis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tapinarof: Dermavant Sciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. B244: AOBiome
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EP262: Escient Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Atopic Dermatitis Inactive Products
20. Atopic Dermatitis Key Companies
21. Atopic Dermatitis Key Products
22. Atopic Dermatitis- Unmet Needs
23. Atopic Dermatitis- Market Drivers and Barriers
24. Atopic Dermatitis- Future Perspectives and Conclusion
25. Atopic Dermatitis Analyst Views
26. Atopic Dermatitis Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Pipeline and Clinical Trials Assessment (2023) | Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, here
News-ID: 3081343 • Views: …
More Releases from DelveInsight Business Research
Limbal Stem Cell Deficiency Market to Surpass USD 2.6 Billion by 2034, Driven by …
In 2023, the Limbal Stem Cell Deficiency (LSCD) market was dominated by the United States, generating nearly USD 1.5 billion in revenue, while Spain represented the smallest market with approximately USD 127 million. This regional distribution is expected to remain consistent throughout the forecast timeline. The US accounted for nearly 103,000 diagnosed LSCD cases, whereas Japan recorded around 37,000 cases, with both countries projected to witness notable growth in patient…
SSc-ILD Market Set to Cross USD 750 Million by 2034, Driven by 10+ Emerging Ther …
The major players operating in the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market include Roche, Prometheus Biosciences, Inc., Merck, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, among others.
DelveInsight's report titled "Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Forecast-2034" delivers a comprehensive analysis of SSc-ILD, covering historical data, projected epidemiology, and evolving market trends across the United States, EU4 (Germany, Spain, Italy, and France),…
Developmental and Epileptic Encephalopathy Treatment Market Poised for Accelerat …
The Developmental and Epileptic Encephalopathy (DEE) treatment market across the seven major markets (7MM) was valued at nearly USD 2.1 billion in 2023 and is expected to register a healthy compound annual growth rate over the forecast period. The United States emerged as the largest contributor, capturing close to 80% of the overall market revenue.
The DEE treatment landscape is undergoing a significant transformation as the limitations of traditional antiepileptic drugs…
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ Therapies and 8+ Co …
DelveInsight's "Polycythemia Vera Pipeline Insight 2025" report delivers an in-depth overview of the Polycythemia Vera pipeline landscape, covering more than 8 companies and 10+ pipeline candidates. The report analyzes both clinical-stage and preclinical assets, offering detailed drug profiles across various stages of development. It also evaluates Polycythemia Vera therapies based on product classification, development stage, route of administration, and molecular category, while additionally spotlighting inactive or discontinued pipeline assets.
Explore the…
More Releases for Atopic
Rising Prevalence Of Atopic Dermatitis Is A Key Catalyst For The Growth Of The A …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Atopic Dermatitis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The scope of the atopic dermatitis market has experienced substantial expansion recently, projected to increase from $8.61 billion in 2024 to reach $9.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.7%;…
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
